2019
DOI: 10.1021/acs.oprd.9b00050
|View full text |Cite
|
Sign up to set email alerts
|

Manufacture of the PI3K β-Sparing Inhibitor Taselisib. Part 2: Development of a Highly Efficient and Regioselective Late-Stage Process

Abstract: A highly efficient and regioselective manufacturing route for the phosphoinositide 3-kinase β-sparing inhibitor taselisib was developed. Highlights of the synthesis include: (1) magnesium-mediated formation of a challenging cyclic amidine;(2) regioselective imidazole construction via alkylation/condensation with bromopyruvic acid; and (3) triazole formation with 2-isopropyl acetamidrazone to generate the key bromobenzoxazepine core intermediate. Subsequent highly efficient one-pot palladium-catalyzed Miyaura b… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
4
3

Relationship

0
7

Authors

Journals

citations
Cited by 13 publications
(2 citation statements)
references
References 18 publications
0
2
0
Order By: Relevance
“…The process characterization methodology outlined in this publication is elaborated with an example in the manufacturing process for the taselisib drug substance . In this example, step product triazole 3 is formed by condensation of carboxylic acid 1 with hydrazonium chloride 2 .…”
Section: Process Designmentioning
confidence: 99%
“…The process characterization methodology outlined in this publication is elaborated with an example in the manufacturing process for the taselisib drug substance . In this example, step product triazole 3 is formed by condensation of carboxylic acid 1 with hydrazonium chloride 2 .…”
Section: Process Designmentioning
confidence: 99%
“…The Suzuki-Miyaura coupling is one of the widely used reactions in pharmaceutical synthesis. For example, St-Jean and coworkers [7] from Genentech developed an efficient late-stage synthetic method for PI3K β-Sparing Inhibitor taselisib 6 [8], which has been demonstrated to have increased activity against PIK3CA mutant breast cancer. A one-pot Miyaura borylation, Suzuki-Miyaura coupling, and saponification to produce 5 from 1 were described.…”
Section: Suzuki-miyaura Couplingmentioning
confidence: 99%